Trial Profile
Comparison of effects of aliskiren-based combination therapy between CCB and ARB in hypertensive patients with chronic kidney disease.
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 12 May 2016
Price :
$35
*
At a glance
- Drugs Aliskiren (Primary) ; Amlodipine; Valsartan
- Indications Hypertension
- Focus Biomarker; Therapeutic Use
- 04 Jul 2012 Status changed from recruiting to discontinued as reported by University Hospital Medical Information Network - Japan record.
- 03 Dec 2011 New trial record